The treatment combines a new drug, inavolisib, with two older breast cancer drugs, fulvestrant (Faslodex ®) and palbociclib (Ibrance ®) . Inavolisib, which targets PIK3CA mutations, appears to be a ...

Along with their alluring beauty, minerals — like scientific ideas — open a window onto the history of the world, Dr. Massagué says.

My group focuses on understanding cell signaling pathways primarily linked with the ubiquitin and autophagy systems and frequently altered in diseases, including neurodegenerative disease. To this end ...

This seminar is open to the research community.

As a parent, learn how to navigate sensitive, open conversations with children and teens about your cancer diagnosis.